Congratulations to Dr. Joel Braunstein, CLP Board Member and CEO of C2N Diagnostics, whose team has been awarded the 2025 HUPO Science and Technology Award.
Recognized for their innovative blood biomarker tests for Alzheimer’s disease, C2N’s work is expanding access to early, accurate diagnosis and advancing the mission of proteomics-driven precision medicine. We celebrate this well-deserved recognition ahead of the HUPO 2025 World Congress in Toronto.
